> Home > News & Events

May 12 - Vetnosis Publishes Innovation & Generic Insight

Edinburgh, UK - 11th May 2012 - Vetnosis publishes Innovation & Generic Insight

Vetnosis publishes Innovation & Generic Insight, a unique analysis and benchmarking study of veterinary pharmaceutical innovation and generics in 2011 and trends in the last decade.

Innovation is the fundamental driver of profitable growth in the animal health industry but also represents one of the largest costs and greatest risks while the role of generics has evolved significantly in recent years.

An in-depth, independent analysis of veterinary pharmaceutical innovation and generics is critical business intelligence for any R&D led or generic company that wants to understand recent developments and long-term trends in novel innovation and generics.

Innovation & Generic Insight is a 308 slide report that delivers innovation and generic data, analysis, benchmarking and comment by company, product group, species, country and approval type in three parts:

Part 1:  Innovation Insight
A.    Novel API 2001-2011
B.    Novel Innovations in 2011

Part 2:  Generic Insight
A.    Generic API 2001-2011
B.    Generics in 2011

Part 3:  Emerging Themes

We have analysed and benchmarked the novel and generic innovations of all 97 companies that received product approvals in 2011.

"One of the questions I have been asked most frequently by leadership teams over the years is the importance of innovation and how their organisation measures up.  In recent years, the evolution of generics has also become a hot-topic that has been analysed for the first time in this Study." said Tim Evans, Managing Director of Vetnosis.

The extensive research for Innovation & Generic Insight has analysed the data required to quantify and benchmark novel innovations and generics.  Not only can we demonstrate how innovative each company has been but Innovation & Generic Insight also reveals the contribution of novel innovation and generics to each company.

Innovation Insight is a "must have" study for any R&D led or generic company, containing unique company benchmarking and innovation analysis by company, product group, species, country and approval type.

For further information please visit https://www.vetnosis.com to download a Brochure and Table of Contents or contact Tim Evans.

Tim Evans
Managing Director
T:  +44 (0)131 718 0772
E:  tim.evans@vetnosis.com